<DOC>
	<DOCNO>NCT00432146</DOCNO>
	<brief_summary>Context : Although endocrine surgeon administer Lugol 's solution decrease thyroid gland vascularity , still agreement effectiveness . Objective : The aim clinical trial evaluate thyroid blood flow microvessel density patient Graves ' disease accord Lugol 's solution treatment preoperatively . Design : Retrospective clinical trial . Setting : A tertiary referral center . Method : Thirty-six patient randomly assign preoperative medication Lugol 's solution . Patients group 1 ( n=17 ) receive Lugol 's solution 10 day surgical intervention , whereas patient group 2 ( n=19 ) n't receive . Main Outcome Measures : Blood flow thyroid artery patient Graves ' disease measure color flow Doppler ultrasonography . The microvessel density ( MVD ) assess immunohistochemically Western blot analysis use level expression CD-34 thyroid tissue . The thyroid gland 's weight blood loss measure patient .</brief_summary>
	<brief_title>Effect Lugol 's Solution Patients With Graves ' Disease</brief_title>
	<detailed_description>Thirty-six patient randomly assign preoperative medication Lugol 's solution . Patients group 1 ( n=17 ) receive Lugol 's solution 10 day surgical intervention , whereas patient group 2 ( n=19 ) n't receive . Blood flow thyroid artery patient Graves ' disease measure color flow Doppler ultrasonography . The microvessel density ( MVD ) assess immunohistochemically Western blot analysis use level expression CD-34 thyroid tissue . The thyroid gland 's weight blood loss measure patient .</detailed_description>
	<mesh_term>Graves Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Lugol 's solution</mesh_term>
	<criteria>Graves disease Anticoagulant usage , Previous thyroid operation , Refused participate study .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>61 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Graves ' disease , Lugol 's solution</keyword>
</DOC>